Funders › TX › Foundation for Angelman Syndrome Therapeutics › 2023
Grants paid by Foundation for Angelman Syndrome Therapeutics, tax year 2023
EIN 26-3160079 · Austin, TX · Form 990, Schedule I · NTEE H12
In tax year 2023, Foundation for Angelman Syndrome Therapeutics (EIN 26-3160079) reported 17 grants paid totaling $5,572,273. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2023
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2023 | University of Pennsylvania Philadelphia, PA | A | $1,853,255 | paid | UPENN 2023: RESEARCH, COLLABORATION & LICENSE AGREEMENT | 202423209349327812 |
| 2023 | Rush University Medical Center Chicago, IL | A | $1,287,600 | paid | RUSH COE | 202423209349327812 |
| 2023 | Boston Children's Hospital Boston, MA | A | $458,118 | paid | FT2022-006: ABOM - NATURAL HISTORY STUDY | 202423209349327812 |
| 2023 | Texas A&m University College Station, TX | A | $267,142 | paid | FT2019-008: TRANSLATIONAL RESEARCH IN PIG MODEL OF AS | 202423209349327812 |
| 2023 | Yale University New Haven, CT | A | $257,475 | paid | FT2020-006: GENERATION AND CHARACTERIZATION OF A NEW AS MOUSE MODEL THAT RECAPITULATES THE LARGE DELETION OF HUMAN 15Q11-Q13 AND A CONTROL LINE THAT CARRIES A DELETION OF ALL GENES IN 15Q11-Q13 BUT UBE3A | 202423209349327812 |
| 2023 | Keck Graduate Institute of Applied Life Sciences Claremont, CA | A | $250,000 | paid | FT2022-002: TARGETING ANGELMAN SYNDROME THERAPEUTICS TO THE BRAIN UTILIZING NOVEL CELL PENETRATING PEPTIDES | 202423209349327812 |
| 2023 | Children's Research Institute Washington, DC | A | $246,600 | paid | FT2022-003: PEAK ALPHA FREQUENCY AS AN EEG BIOMARKER FOR ANGELMAN SYNDROME | 202423209349327812 |
| 2023 | Brown University Providence, RI | A | $194,000 | paid | FT2022-005: DEVELOPMENT OF BDNF POTENTIATING THERAPEUTICS FOR MOTOR AND COGNITIVE DYSFUNCTION IN AS | 202423209349327812 |
| 2023 | North Carolina State University Raleigh, NC | A | $178,887 | paid | FT2022-001: MICROPROBE-INTEGRATED HUMAN ORGANOID ARRAYS TO STUDY AS GENOTYPES AND THERAPEUTICS | 202423209349327812 |
| 2023 | North Carolina State University Raleigh, NC | A | $161,647 | paid | FT2021-002: ISOGENICALLY CONTROLLED HUMAN CELL LINES TARGETING ABERRANT IMPRINTING GENOTYPES AND A NEW REPORTER CELL LINE. | 202423209349327812 |
| 2023 | The Regents of the University of California San Francisco San Francisco, CA | A | $93,702 | paid | FT2023-002: DEVELOPING A CRISPRA THERAPY FOR THE CLASSI/II DELETION GENOTYPE OF ANGELMAN SYNDROME | 202423209349327812 |
| 2023 | Duke University Charlotte, NC | A | $75,445 | paid | FT2018-005 AMENDED: GPIC-COMM | 202423209349327812 |
| 2023 | Regents of the University of California Davis Davis, CA | A | $75,000 | paid | FT2022-007: GASTROINTESTINAL BIOMARKERS IN PRECLINICAL MODELS OF ANGELMAN SYNDROME | 202423209349327812 |
| 2023 | Brown University Providence, RI | A | $50,500 | paid | PD2023-001: POSTDOCTORAL FELLOWSHIP PROGRAM | 202423209349327812 |
| 2023 | Yale University New Haven, CT | A | $50,500 | paid | PD2022-001: POSTDOCTORAL FELLOWSHIP PROGRAM | 202423209349327812 |
| 2023 | North Carolina State University Raleigh, NC | A | $43,087 | paid | FT2022-008: STEM CELL LINE IN-VITRO INFRASTRUCTURE CREATED AT NCSU FOR INDUSTRY AND ACADEMIC SUPPORT | 202423209349327812 |
| 2023 | North Carolina State University Raleigh, NC | A | $29,315 | paid | RADAR 2023-2137 | 202423209349327812 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990 e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.